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The life cycle of Kaposi’s sarcoma-associated herpesvirus (KSHV) consists of latent and lytic replication phases. During latent
infection, only a limited number of KSHV genes are expressed. However, this phase of replication is essential for persistent
infection, evasion of host immune response, and induction of KSHV-related malignancies. KSHV reactivation from latency
produces a wide range of viral products and infectious virions. The resulting de novo infection and viral lytic products modulate
diverse cellular pathways and stromal microenvironment, which promote the development of Kaposi’s sarcoma (KS). The
mechanisms controlling KSHV latency and reactivation are complex, involving both viral and host factors, and are modulated
by diverse environmental factors. Here, we review the cellular and molecular basis of KSHV latency and reactivation with a focus
on the most recent advancements in the ﬁeld.
1.Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) was iden-
tiﬁed in an acquired immune deﬁciency syndrome (AIDS)
patient with Kaposi’s sarcoma (KS) [1]. Extensive studies
have shown that KSHV is etiologically associated with KS, a
vascularmalignancy ofendothelialcellorigin, mostly involv-
ing the skin, oral cavity, and/or other subcutaneous tissues
[2]. Clinical features of KS lesions include proliferation of
KSHV latent nuclear antigen- (LANA- or LNA-) positive
spindle-shaped tumor cells, extensive “slit-like” vascular
networks, and inﬁltration of various inﬂammatory cells and
red blood cells [3]. There are four clinical forms of KS: (1)
classical KS, which is mainly seen in elderly men of Mediter-
ranean and Eastern European origins, (2) endemic KS in
Africa, (3) epidemic AIDS-related KS (AIDS-KS), and (4)
iatrogenic KS in patients undergoing organ transplantation-
related immunosuppression regimens. In Western countries,
AIDS-KS is the most prevalent form of KS, which is also
the most common malignancy in HIV patients [3]. KSHV
is etiologically associated with all forms of KS. In addition to
KS,KSHVisalso causally implicatedinseveralnon-Hodgkin
lymphomas including primary eﬀusion lymphoma (PEL)
and multicentric Castleman’s disease (MCD) [4–6].
Like all herpesviruses, the life cycle of KSHV consists of
latent and lytic replication phases [7]. In immunocompetent
individuals, KSHV establishes latent infection following an
acute infection. During latent infection, KSHV genome per-
sists as a circular double-stranded DNA molecule (episome)
in the nucleus with most viral genes being silenced except
a few viral latent genes located in the latency locus. As a
result, there is no production of virions. Latent infection
allows KSHV to evade the host immune surveillance and
facilitate the establishment of a lifelong persistent infection.
KSHV latent cells constitute a reservoir of chronic viral
infection tightly controlled by the host immune system.
Latent infection has an essential role in the development of
KSHV-associated malignancies because most tumor cells in
KS, PEL, and MCD are latently infected by KSHV.2 Advances in Virology
In immunocompromised hosts, KSHV latent cells can
be reactivated into lytic replication expressing all viral lytic
genes and producing infectious virions. One of the ﬁrst lytic
g e n e st ob ee x p r e s s e di sa ni m m e d i a t ee a r l y( I E )g e n eR T A
(ORF50), followed by early genes such as MTA (ORF57)
and K-bZIP (ORF-K8), and late genes such as major capsid
protein ORF25. Viral DNA replication, capsid packaging,
and virion maturation and egress also follow the expression
of viral lytic genes, leading to the completion of viral
lytic replication cycle. Lytic DNA replication generates a
linear form of double-stranded DNA molecules, one copy of
which is packaged into each virion. For herpesviruses, lytic
replicationnotonlyproducesinfectiousvirionsforspreading
but also often causes their associated diseases. For KSHV,
viral lytic products and de novo infection promotes cell
proliferation, angiogenesis, and local inﬂammation, leading
to the initiation and progression of KS tumors [8–19]. The
importance of KSHV lytic replication for supporting KS
tumors is substantiated by clinical observation that KS pro-
gression is tightly correlated with KSHV lytic antibody titers
and viral loads in patients [20–27]. In KS tumors, a small
subset of cells also undergoes spontaneous lytic replication.
Inhibition of KSHV lytic replication with antiherpesviral
drugs that block lytic replication causes KS tumor regression
[28–30].
Since both latent and lytic replication phases are impor-
tant for the development of KS tumor, understanding the
mechanisms of KSHV latency and reactivation might hold
the key to elucidating KSHV-induced pathogenesis, as well
as developing novel therapeutic approaches, and thus has
been the hot topic in the ﬁeld. Here we attempt to review
the most recent advancements in the molecular and cellular
mechanisms that regulate KSHV life cycle.
2.Mechanism of KSHVLatency
A successful KSHV latency program must ensure (1) silenc-
ing ofviral lyticgene expression; (2)survival and continuous
proliferation of the infected cells; (3) stable maintenance,
replication,and propersegregation oftheviral episomesinto
daughter cells during mitosis. Although how these criteria
are achieved is still not fully understood, it is clear that
establishment of viral latency is mediated by complex host-
virus interactions involving both the host defense systems
and the viral surviving capacities [31].
2.1. Host Factors. The host immune surveillance plays a
key role in eliminating the virus during an acute infection
and keeping the virus in check throughout the lifelong
persistent infection. However, it is not known whether host
immune responses directly suppress KSHV lytic replication.
At the cellular level, several studies have demonstrated that
KSHV acute infection elicits antiviral defenses, which inhibit
viral gene expression and lytic replication. Attachment of
KSHV virions to the target cells triggers a rapid secretion of
interferon-beta (IFN-β) and activates interferon regulatory
factor 3 (IRF-3) to induce the expression of host IFN-
stimulated antiviral genes [32]. KSHV glycoprotein K8.1
appears to trigger this event. In addition, interferon-alpha
(IFN-α) blocks the initiation of lytic replication while
interferon-gamma (IFN-γ) inhibits the late steps of lytic
replication [33–38]. Furthermore, cellular interferon regu-
latory factor 7 (IRF-7) negatively regulates lytic replication
by competing with the lytic switch protein RTA for binding
to RTA-responsive element (RRE) in the MTA promoter
[39, 40]. IRF-7 participates in IFN-α repression of RTA-
mediated transactivation [39]. The inhibition of lytic gene
expression and replication by antiviral responses promotes
viral latency and survival of the infected cells. Thus, KSHV
has evolved to adapt to the host innate antiviral responses
to achieve infection and establish latency in the host. In the
same time, KSHV promotes latency by modulating multiple
cellularpathwaystofavorcellgrowthandsurvival,which will
be discussed in the latter section.
2.2. Viral Genome and Viral Genes. During latency, KSHV
persists as circular episomes associated with histones in the
nucleus [41]. These episomes are assembled into nucleo-
somal structures that resemble bulk cellular chromatin. All
viral lytic genes are near complete shut down during latency.
When switched into lytic replication, the chromatins of
KSHV genomes undergo signiﬁcant modiﬁcations [42, 43].
Tworecentstudieshaveexaminedtheepigeneticlandscapeof
KSHV genomes using high-resolution tiling microarrays in
conjunction with immunoprecipitation of methylated DNA
(MeDIP) or modiﬁed histones (chromatin IP, CHIP) [44,
45]. During de novo infection of endothelial cells, KSHV
genomes undergo heavy methylation at CpG dinucleotides
[44]. These alterations of DNA methylation patterns are
accompanied by speciﬁc histone modiﬁcations leading to the
rapid establishment of latency. Interestingly, viral genomes
are not uniformly modiﬁed. In particular, activating histone
modiﬁcation marks such as H3K9/K14-ac and H3K4-me3
persist at several loci including the RTA promoter [44].
Similarly, in latent BCBL-1 cells, KSHV genomes contain
both activating marks H3K9/K14-ac and H3K4-me3 as well
as repressive marks H3K9-me3 and H3K27-me3, which
are mutually exclusive on most part of the latent genome
[45]. Both activating mark H3K4-me3 and repressive mark
H3K27-me3 are also present in region encoding RTA and
ORF48,whichchangeuponviralreactivation. Theseﬁndings
obviously have generated new questions, one of which is
how viral lytic regions are suppressed during viral latency?
Intriguingly, rapid and widespread deposition of H3K27-
me3 is present across the entire viral genomes during de
novo infection [44]. These bivalent modiﬁcations are also
presentinlatentcells[45].Becausethisbivalentmodiﬁcation
is known to repress transcription in spite of simultaneous
presence of activating marks, it is postulated that these
modiﬁcation patterns could induce a poised state of repres-
sion during latency that could be rapidly reversed once the
lytic cycle is triggered. Interestingly, bivalent modiﬁcation
mark H3K27-me3 is colocalized with EZH2, an H3K27-me3
histone methyltransferase of the polycomb group proteins
(PcG) [45]. During viral reactivation, EZH2 is dissociated
from the regions encoding for IE genes, accompanying theAdvances in Virology 3
decrease of H3K27-me3 and the increase of transcriptional
activities.
Together, results of these studies suggest that epigenetic
modiﬁcations of KSHV genome through histone modiﬁ-
cations are essential in silencing lytic gene expression and
promoting viral latency [44, 45]. Interestingly, there is a
substantial reduction of repressive mark H3K27-me3 in
the latency locus compared to the rest of KSHV genome
duringlatency.ThisregionencodesLANA,vCyclin(ORF72),
vFLIP (ORF71), and a cluster of 25 matured microRNAs
(miRs) derived from 12 precursor miRs (miR-K1-12) [46,
47]. LANA, vCyclin, and vFLIP are transcribed as multiple
polycistronic mRNAs, including a 5.8kb unspliced and a
diﬀerentiallyspliced 5.3kbmRNAs, bothof which encodeall
three ORFs, and another 2.8kb mRNA, which only encodes
vCyclin and vFLIP [46]. Consistent with results of the epi-
genetic studies, these proteins, along with the miRs, are the
only viral genes expressed in latently infected KS cells. They,
along with LANA-2/vIRF3 (ORF-K10.5), are also the only
ones expressed in latently infected PEL cells. It is suggested
that the expression of latent genes in the latency locus might
also be controlled at the chromatin level [48]. Cohesins and
the 11-zinc ﬁnger protein CCCTC-binding factor (CTCF),
which mediate sister chromatin cohesion and functions at
chromatin boundaries, respectively, play key roles in the
structuralandfunctionalorganization ofchromosomes [49].
Both cohesion and CTCF bind to KSHV episomes and have
speciﬁc binding sites located within the control region of the
major latency transcript that encodes LANA, vCyclin, cFLIP,
and miRs. Disruption of the interactions between these
trans and cis elements not only results in failure in colony
formation in 293 cells but also leads to enhanced expression
of adjacent KSHV lytic genes such as vOX (ORF14) and
vGPCR (ORF-K14). Interestingly, KSHV genes regulated by
CTCF cohesin are under cell cycle control and that mutation
of the CTCF binding sites abolished cell cycle-regulated
transcription [48]. Cohesin subunits assembled at the CTCF
binding sites and bound CTCF proteins in a cell cycle-
dependent manner. Subcellular distribution of CTCF and
colocalization with cohesins also varied across the cell cycle.
RAD21and SMC1are associated with thecellularCTCFsites
at mammalian c-myc promoter and H19/Igf2 imprinting
controlregion.Itispostulatedthatthislatencycontrolregion
is occupied with the cellular chromatin boundary factor
CTCF and chromosome structural maintenance proteins
SMC1, SMC3, and RAD21, which comprise the cohesin
complex. Indeed, RAD21 is rapidly dissociated from the
viral genome during reactivation. Knockdown of RAD21
results in a transcriptional upregulation of the lytic genes
vOX and vGPCR, while overexpression of RAD21 represses
transcription of CTCF targeted lytic genes. Furthermore,
a RAD21-CTCF chimeric protein converts CTCF into a
transcriptional repressor of KSHV genes that are normally
activated in the G2 phase of cell cycle. Thus, CTCF-cohesin
complex plays a critical role in regulating cell cycle control of
viral gene expression during latency, and failure to maintain
cell cycle control of latent transcripts inhibits host cell
proliferation and survival.
Because LANA, vCyclin, vFLIP, and the miRs are located
in the latency locus and expressed during latency, they are
likely to contribute to KSHV latency. Extensive studies have
indeed indicated that all of these genes play important roles
in suppressing KSHV lytic gene expression and promoting
latency. Furthermore, they are also involved in KSHV-
induced malignant transformation bypromoting cell growth
and survival.
2.2.1.LANA. LANAencodedbyORF73,alsoknownaslatent
nuclear antigen (LNA), was initially identiﬁed as a doublet
of 220–230kDa nuclear proteins by Western blotting, and
as the most immunodominant latent antigen in KS patients
[50]. LANA is strongly expressed in KSHV-infected cells
throughout the virus life cycle [50–54]. LANA is responsible
for KSHV episomal DNA replication, maintenance, and
segregation into daughter cells during mitosis [55–58].
The terminal repeats (TRs) in KSHV genome contain a
DNA replication origin cis-element, and LANA is a trans-
acting protein that preferentially binds to TRs to form a
DNA-protein complex [59–61]. In lymphoblasts, LANA is
necessary and suﬃcient for the persistence of an artiﬁcial
episome containing two TR units [62–64]. Immunostaining
reveals that LANA is colocalized with the artiﬁcial episomes
in nuclei and along mitotic chromosomes, supporting a
model in which LANA tethers KSHV DNA to chromosomes
during mitosis to enable the eﬃcient segregation of KSHV
episomes to progeny cells [60]. Both C- and N-terminals of
LANA mediate its binding to TRs [59, 65–67]. Despite the
absence of a DNA polymerase activity by LANA, the LANA-
TRs complex is suﬃcient for episomal DNA replication
[62], indicating that the complex may recruit cellular DNA
replication machinery to complete viral DNA replication.
Indeed, poly(ADP-ribose) polymerase 1 (PARP1) and other
knownreplicationfactorssuchasoriginrecognitioncomplex
2 (ORC2), CDC6, uracil DNA glycosylase 2 (UNG2), and
Mcm7 bind to TRs [68–73]. The association of TRs with
ORCs is LANA dependent, and both the N- and C-terminals
of LANA are required for this interaction [65, 70, 74, 75].
Thus, LANA’s role in KSHV episomal DNA replication is
mediated through its binding to TRs and recruitment of
cellular DNA replication proteins.
LANA also tethers viral episomes to host chromosomes
during mitosis, ensuring proper partitioning of viral epi-
somes into daughter cells [55]. Fine molecular mapping
identiﬁed amino acids 5 to 22 of LANA as the region
that binds to chromosomes [74–77]. Both methyl-CpG-
binding protein MeCP2 and the 43-kDa protein DEK
interact with LANA and might mediate the tethering [78,
79]. However, LANA also interacts with bromodomain
protein Brd4 through the extra-terminal domain of Brd4
and a carboxyl-terminal region of LANA [80]. Since Brd4
is associated with mitotic chromosomes throughout mitosis
and is colocalized with LANA and KSHV episomes on host
mitotic chromosomes, Brd4 might also be an interacting
protein that mediates LANA tethering on mitotic chromo-
somes. Similarly,LANAisassociated withthenuclearmitotic
apparatus protein (NuMA) [58]. In synchronized cells,4 Advances in Virology
NuMA and LANA are colocalized in interphase cells. During
mitosis, the two proteins are separated from each other at
the beginning of prophase but are reassociated at the end of
telophase and cytokinesis. Silencing of NuMA expression by
siRNAs disrupts the association of NuMA with microtubules
resulting in the loss of KSHV TR plasmids containing the
latent origin of replication. A recent study showed that
LANA is associated with centromeric protein F (CENP-F) as
speckles, some of which are paired at centromeric regions
of a subset of chromosomes in KSHV-infected JSC-1 cells
[81].Moreover, LANAisassociated with kinetochore protein
Bub1 (budding uninhibited by benzimidazole 1) known to
form a complex with CENP-F [81]. The dynamic association
of LANA and Bub1/CENP-F and the colocalization among
Bub1, LANA, and the KSHV episome tethered to the host
chromosome were shown in ﬂuorescence in situ hybridiza-
tion (FISH). Knockdown of Bub1 expression by lentivirus-
delivered shRNA dramatically reduced the number of KSHV
genome copies, whereas no dramatic eﬀect was seen with
CENP-F knockdown. Therefore, the interaction between
LANA and the kinetochore proteins CENP-F and Bub1 is
important for KSHV genome tethering and its segregation
to new daughter cells, and Bub1 potentially plays a critical
role for the long-term persistence of the viral genome in the
infected cells.
Collectively, these results indicate that LANA is essential
in KSHV episomal DNA replication, maintenance, and
segregation of the viral genomes into daughter cells during
mitosis. Consistent with these results, genetic disruption of
LANAledtorapid lossofKSHVgenomesin humancellsand
prevented KSHV from establishing persistent infection [82].
Another important mechanism in which LANA pro-
motes KSHV latency is through inhibition of viral lytic
gene expression. Although LANA positively regulates the
expression of some genes, it also interacts with mSin3 core-
pressorcomplex[83]anda nucleartranscriptional repressive
protein named “KLIP-1” (KSHV LANA-interacting protein
1) to exert a negative regulatory eﬀect on gene transcription
[84]. Consistent with these observations, LANA induces
and relocates RING3 to nuclear heterochromatin regions,
creating a local euchromatic microenvironment around the
viral episomes that are anchored to the heterochromatin [85,
86]. In addition, LANA interacts and recruits DNA methyl-
transferases (Dnmts) to repress gene expression through
chromatinmethylation atthepromoterregions[87].Indeed,
LANA inhibits the expression of RTA at the transcriptional
level [88]. There is evidence that LANA is recruited to RTA
promoter and participates in local chromatin remodeling
to suppress its expression [43]. Interestingly, LANA also
directly interacts with RTA and inhibit its transactivation
activity [89]. LANA physically associates with recombi-
nant signal sequence-binding protein-J kappa (RBP-Jκ) in
vitro and in KSHV-infected cells forming complex on the
RBP-Jkappa cognate sequences [90]. Of note, the RBP-
Jκ binding sites within the RTA promoter are critical for
LANA-mediated repression. Thus, LANA maintains KSHV
latency by targeting a major downstream eﬀector of the
Notch signaling pathway [90]. In agreement with these
data, deletion of LANA increased the expression levels of
all classes of lytic genes including RTA, MTA, vIL-6 (ORF-
K2),ORF59,andORF-K8.1withandwithoutinductionwith
12-O-tetradecanoyl-phorbol-13-acetate (TPA) and sodium
butyrate [91]. This enhancement of viral lytic gene expres-
sion was also observed following overexpression of RTA
with or without simultaneous chemical induction. LANA
mutant cells produced more infectious virions than the
wild-type virus cells did. Furthermore, genetic repair of
the mutant virus reverted the phenotypes to those of wild-
type virus. Together, these results demonstrated that, in the
context of viral genome, LANA contributes to KSHV latency
by inhibiting the expression of RTA as well as inhibiting
its transactivation of downstream genes. Nevertheless, the
expression of RTA and RTA’s transactivation in the LANA
mutant can be further increased by treatment with TPA
and butyrate, indicating that KSHV latency is controlled by
multiple mechanisms [91].
LANA also contributes to latency by promoting cell
growth and survival. LANA interacts with and functionally
inhibits tumor suppressors p53 and pRb to promote growth
and survival of KSHV-infected cells [92–95]. Nevertheless,
LANA inhibition of p53 function is not complete at least
in PEL cells as these cells respond quickly to DNA dam-
aging agents. In addition, LANA stabilizes β-catenin by
binding to the negative regulator GSK-3β,c a u s i n gac e l l
cycle-dependent nuclear accumulation of GSK-3β [96, 97].
Furthermore, LANA stimulates cell cycle progression by
interacting with, stabilizing, and activating oncogene c-Myc
[98]. Interestingly, siRNA knockdown of the expression of
c-Myc in PEL cells caused virus reactivation and increased
the expression of lytic genes in addition to inhibition
of proliferation and increase of apoptosis [99]. c-Myc
overexpression inhibited lytic gene expression and virus
reactivation. These results suggest that c-Myc is required
for maintenance of KSHV latency through suppression of
lytic gene expression and promotion of cell survival and
proliferation and that LANAcontributes to KSHV latency by
stabilizing and activating c-Myc.
2.2.2. vCyclin. vCyclin forms an active kinase complex
with cellular CDK6 to regulate cell cycle progression by
phosphorylating pRb protein, a common substrate of the
cellular cyclin D-CDK6 complex, as well as a large repertoire
of unique cellular substrates such as p27KIP1, p21CIP1,
ORC1,andCDC6involvedincellcycleregulation[100–104].
Thus, vCyclinmight contributeto KSHVlatency by promot-
ing cellular proliferation. The vCyclin-CDK6 complex also
phosphorylates nucleophosmin (NPM), facilitating NPM-
LANA interaction and recruitment of HDAC1 to regulate
KSHV latency [105]. Nevertheless, the role of vCyclin in
regulating KSHV life cycle remains largely unclear. Further
study in the context of virus infection by reverse genetics
might shed light on its function.
Interestingly, murine gammaherpesvirus 68 (MHV68),
which is closely related to KSHV, also encodes a cyclin
homolog. Deletion of vCyclin has little eﬀect on MHV68
growth kinetics and viral titer in vitro [106]. However, the
mutant virus fails to reactivate for lytic replication in vivoAdvances in Virology 5
following acute infection in mice. The growth deﬁciency of
the mutant virus is not mediated by T or B cells because it is
present in both immune competent BALB/cmice and T- and
B-cells deﬁcient SCID mice [106]. These results indicate that
MHV68 vCyclin might mediate important functions in the
acute infection and is required for eﬃcient reactivation from
latency. Given the close phylogenic relationship between
KSHV and MHV68, it is possible that KSHV vCyclin might
have similar functions.
2.2.3. vFLIP. vFLIP, like its cellular counterpart cFLIP,
inhibits Fas ligands-induced apoptosis by inhibiting
procaspase-8 activation [107]. In addition, vFLIP activates
both the canonical and noncanonical NF-κBp a t h w a y s
to promote cell survival [108–111]. Thus, vFLIP likely
contributes to KSHV latency by promoting cell survival.
While the eﬀectofNF-κB pathway onKSHVlytic replication
is controversial and appears to be context dependent [112–
115], genetic deletion of vFLIP from the KSHV genome
showed that it inhibits the expression of RTA and suppresses
KSHV lytic replication [116]. Mechanistically, vFLIP
suppresses viral gene expression by inhibiting AP-1 pathway
through activation of NF-κB pathway. Thus, vFLIP regulates
KSHV latency by activating a key cellular survival pathway
to promote cell survival and inhibiting viral lytic replication.
2.2.4. MicroRNAs. Among the 12 pre-miRs encoded by
KSHV, ten (miR-K1–9 and -K11) form a cluster in an
intron between vFLIP and kaposin, while the remaining two
reside in the coding region (miR-K10) and 3UTR of ORF-
K12 (miR-K12), respectively [117–119]. All KSHV miRs
are expressed during latency, but the expression of miR-
K10 and -K12 is further increased upon lytic induction
[117–119], suggesting their potential roles in viral latency.
Indeed, genetic deletion of the miR cluster inhibits the
expression of KSHV lytic genes in both uninduced cells
and cells induced for lytic induction [120, 121]. Among
these miRs, miR-K9 directly targets RTA to regulate viral
replication [122]. Several KSHV miRs also regulate viral
life cycle through indirect mechanisms. miR-K5, -K9, and
-K10a/b target Bcl-2-associated factor (BCLAF1) to inhibit
apoptosis and regulate lyticreplication [123], while miR-K4-
5p epigenetically regulates lytic replication by targeting Rb-
like protein 2 (Rbl2) to increase the expression of DNMT1,
-3a and -3b [124]. miR-K1 targets IκBα to increase cellular
NF-κBa c t i v i t y[ 120]. Expression of miR-K1 in mutant cells
rescues the NF-κB activity and inhibits viral lytic replication,
while suppression of miR-K1 in KSHV-infected BCP-1 cells
increases the IκBα protein level, suppresses NF-κBa c t i v i t y ,
and increases the expression of viral lytic genes [120].
Because NF-κB pathway is involved in cell growth and
survival, immunity, inﬂammation, and tumor development,
s i m i l a rt ov F L I P ,m i R - K 1m i g h td i r e c t l yc o n t r i b u t et ot h e
pathogenesis of KSHV-induced malignancies in addition to
its function in regulating viral life cycle. miR-K3 suppresses
viral lytic replication by targeting nuclear factor I/B, which
is shown to activate the RTA promoter [121]. miR-K11 is an
ortholog of human miR-155 [125, 126]t h a tt a r g e t sB A C H 1 .
Consequently, several BACH1-regulated genes including
heme-oxygenase-1 (HMOX-1) and xCT are upregulated
by miR-K11 [127]. HMOX-1 enhances cell survival and
proliferation, while xCTreplenishes intracellular glutathione
stores to maintain cell viability in an environment of oxida-
tive stress. Thus, by targeting the transcriptional repressor
BACH1, miR-K11 promotes host cell survival, particularly
in an oxidative stress environment. Finally, KSHV miR-
K10a targets TNF-like weak inducer of apoptosis (TWEAK)
receptor (TWEAKR) [128]. Downregulation of TWEAKR
by miR-K10a results in reduced levels of TWEAK-induced
caspase activation and apoptosis as well as decrease in
expression of proinﬂammatory cytokines IL-8 and MCP-1
in response to TWEAK. Thus, miR-K10a protects cells from
apoptosis and suppresses proinﬂammatory responses, which
might contribute to KSHV latency [128].
2.2.5. Antisense RNAs. Antisense transcripts are widespread
in mammalian cells [129]. Global transcriptome analyses
show that up to 70% of transcripts have antisense partners
and that perturbation of antisense RNAs can alter the
expression of the sense genes. The biological functions of
these antisense RNAs are not fully understood. Analyses of
KSHV-infected cells by deep sequencing and genome-wide
tiling array revealed extensive antisense transcription during
lytic replication throughout the KSHV genome, including a
10kb RNA antisense to the major latency locus [130, 131]. It
is postulated that these antisense RNAs might play a role in
KSHV life cycle by regulating viral chromatins. Interestingly,
an antisense transcript to RTA mRNA does not regulate
RTA expression but encoding small peptides with unknown
functions [132].
In summary, each of the KSHV latent genes/products
contributes to KSHV latency by playing a distinct but
complementary role (Figure 1). Their functions are best
illustrated by reverse genetic analyses showing that deletion
ofany oneoftheselatentgenesisnotsuﬃcient formaximum
productive lytic replication albeit an enhanced viral lytic
replication program. Thus, KSHV has evolved multiple
synergistic mechanisms to cope with complex host and
environmental factors so as to accomplish successful latency.
3.Mechanism ofKSHVReactivation
3.1. Factors That Induce KSHV Reactivation from Latency.
As discussed earlier, the immune system plays a key role
in controlling KSHV life cycle. Indeed, productive lytic
replication frequently occurs when the host suﬀers from
a temporary or permanent immune suppression [3, 133].
Nevertheless, immune suppression may only provide a
favorable physiological environment for the virus to thrive.
While it might be necessary, it is likely insuﬃcient to trigger
KSHV switch from latency into lytic replication. Additional
physiological or environmental factors are likely required to
induce KSHV lytic replication.
3.1.1.Hypoxia. Hypoxiaissuggestedtobeapossible cofactor
for KSHV reactivation based on the clinical observation that6 Advances in Virology
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Figure 1: Schematic illustration of mechanisms of KSHV latency and reactivation. During primary infection, KSHV activates innate
immune responses such as IFN-α/β and IRFs and multiple cell survival pathways including NF-κB, c-Myc, and PI3K/AKT, all of which
repress KSHV lytic replication. Expression of KSHV latent products including LANA, vCyclin, vFLIP, and a cluster of miRNAs also inhibits
KSHV lytic replication. As a result, KSHV establishes latency following primary infection. During latency, most parts of viral genome are
epigenetically silenced and contain both active and repressive histone marks (black triangle) with the exception of the latent locus, which is
transcribed andcontainsonlyactive histonemarks (blackcycle).KSHVlatentproducts enhance/maintainlatency by promotingcell survival
and facilitating the viral episome replication and segregation. Several physiological factors including hypoxia, HIV infection, inﬂammatory
cytokines, oxidative stress, and ROS can induce RTA expression by activating speciﬁc cellular pathways and transcriptional factors including
MEK/ERK, JNK, p38, AP-1, Ets-1, HIF1/2, PKC, and Notch. RTA interacts with several host proteins such as XBP-1, Notch, and C/EBPα,a s
well as viralproteins such as MTA and kb-ZIP,to quicklyremove the repression histonemarkson KSHV genome,resulting in the expression
of viral lytic genes and activation of the entire viral lytic transcriptional program.
KS tumors often appear on body parts such as feet and
arms, where bloodand oxygensupplymight be relatively low
compared to other body parts. In support of this hypothesis,
it was demonstrated that hypoxia could induce KSHV lytic
replicationinPELcells[134].Hypoxiainducesaccumulation
of hypoxia-inducible factors (HIF1/2). In KSHV genome,
promoters of at least two lytic genes, RTA and ORF34,
contain functional hypoxia response elements (HREs) [135,
136]. The RTA promoter mainly responds to HIF-2α while
the ORF34 promoter responds to both HIF-1α and HIF-2α
[135, 136]. In fact, the ORF34-37 promoter region has six
consensus HREs, one of which (HRE2)plays a critical role in
hypoxia induction of a 3.4kb transcript encoding ORF35-
37 and a 4.2kb transcript encoding ORF34-37. Hypoxia
also induces activation of transcription factor X-box binding
protein 1 (XBP-1), which can synergistically transactivate
RTA promoter with HIF-1αto induceKSHVlytic replication
under hypoxia condition [137]. In addition, LANA switches
from repressive to active role by interacting with HIF-1α to
upregulate RTA expression under hypoxia condition [138].
3.1.2. HIV and Other Infections. AIDS-KS is more aggressive
than other forms of KS. HIV infection is suspected to
contribute to KSHVreactivation. HIV-1 infection of PEL cell
line BC-3 enhances KSHV lytic replication [139, 140], and
HIV-1 transactivator Tat is suﬃcient to induce expression of
RTA and KSHV lytic replication [141]. In addition, infection
by other viruses such as herpes simplex virus-1, human
herpesvirus 6 (HHV6), or cytomegalovirus (CMV) may
causeKSHVreactivation[142–144].Toll-likereceptors7and
8(TLR7/8),which are activated bysome viral infections, also
mediate KSHV reactivation [145].
3.1.3. Inﬂammation and Inﬂammatory Cytokines. Reactiva-
tion of KSHV by HIV and other viruses could be indirectly
mediated by inﬂammation cytokines. While CD4+ T-cellAdvances in Virology 7
counts are often low in HIV-infected patients, phago-
cytes and other types of lymphocytes continue to elicit
inﬂammatory responses, resulting in production of various
inﬂammatory cytokines. Some inﬂammatory cytokines that
are highly expressed in KS lesions can reactivate KSHV
[146]. While IFN-γ induces lytic replication in cultured
BCBL-1 cells [34, 147], IFN-α inhibits lytic replication, and
other cytokines such as IL-1, IL-2, IL-6, TNF-α, bFGF, and
granulocyte-macrophage colony stimulating factor (GM-
CSF)havelittleeﬀect[33]. Inendothelialcells, inﬂammation
cytokines inhibit spontaneous KSHV lytic gene expression
[148]. Obviously, the roles of cytokines in KSHV life cycle
and theirmechanisms ofregulation remain unclearand need
to be further deﬁned.
3.1.4. Oxidative Stress and Reactive Oxygen Species (ROS).
Since inﬂammation and oxidative stress are features of KS
tumors, we speculate that reactive oxygen species (ROS)
producedfrom these two physiological eventsmight mediate
KSHV reactivation. Indeed, we have shown that ROS hydro-
gen peroxide (H2O2)i ss u ﬃcient to induce lytic replication
in KSHV-infected BCBL-1 cells by activating the MAPK
pathways, which are attenuated by H2O2-speciﬁc antioxi-
dants [149]. Interestingly, ROS induced by inhibition of NF-
κB pathway also triggers KSHV reactivation [150], which is
consistent with the observation that NF-κBp a t h w a yi n h i b i t s
KSHV lytic replication by suppressing AP-1 pathway [116].
Importantly, induction of KSHV reactivation by hypoxia
and proinﬂammatory cytokines is mediated by ROS [149].
H2O2 is expected to be abundant in all clinical forms of
KS: AIDS-KS patients associated with immunosuppression
and inﬂammation [151], classical KS patients associated
with ageing [152], transplant KS patients associated with
immunosuppression [153], and African KS patients associ-
ated with excess iron [154, 155]. Thus, ROS could be the
common physiological cue that converges diﬀerent KSHV
reactivation signals. LowlevelsofROSare knowntopromote
proliferation, cell survival, angiogenesis, and inﬂammation
through REDOX signaling. Indeed, treatment with antioxi-
dantN-acetyl-L-cysteine(NAC)notonlyinhibitsKSHVlytic
replication in vivo but also slows the development of PEL
in a mouse xenograft model [149]. These results indicate
that REDOX signaling regulates KSHV lytic replication in
vivo,and antioxidants and anti-inﬂammation drugs couldbe
promising preventive and therapeutic agents for eﬀectively
targeting KSHV replication andK S H V - r e l a t e dm a l i g n a n c i e s
[149]. Because many of these agents are widely available and
aﬀordable, their use is attractive, particularly in the African
settings [149].
Additional factors might also contribute to KSHV reac-
tivation. For instance, several studies suggested that speciﬁc
cell cycle phases and cell diﬀerentiation might regulate
KSHV reactivation [156, 157]. In addition to the synergistic
eﬀect with hypoxia condition, XBP-1 alone can eﬀectively
initiate KSHV reactivation by activating the RTA promoter
[157, 158]. Of note, splicing of the XBP-1 mRNA, which
speciﬁcally occurs during B-cell diﬀerentiation, is critical in
triggering KSHV reactivation. Thus, KSHV reactivation may
be integrated into host cell diﬀerentiation program. Further-
more, someenvironmental factorssuchasexcessiveexposure
t oh i g hc o n c e n t r a t i o no fi r o n( F e ++) or certain chemicals or
diets have been suggested to be the risk factors for KS and
might induce KSHV lytic replication [159–162].
3.2. Cellular Signaling Pathways Involved in Regulation of
KSHV Lytic Replication. While various host and environ-
mental factors can trigger KSHV reactivation, most of them
exert their eﬀects indirectly by activating speciﬁc cellu-
lar signaling pathways. Intracellular calcium mobilization
induces Ca++-dependent KSHV reactivation, and inhibition
of calcineurin signaling blocks KSHV reactivation [163].
Protein kinase C delta (PKCdelta) is also required for
KSHV lytic replication [164]. Treatment with PKCdelta
inhibitors GF109203X and rottlerin inhibits TPA-induced
KSHV lytic replication. Systematic screening has identiﬁed
a number of additional cellular factors and their associated
pathways that might mediate KSHV reactivation [165].
The Raf/MEK/ERK/Ets-1 pathway is one of the pathways
mediating KSHV reactivation [165]. Indeed, the promoters
of RTA, MTA and K-bZIP, and origins of lytic replication
(OriLyts) contain functional DNA-binding sites for AP-1,
which is downstream of the pathway, and are responsive to
AP-1 activation [166–168]. In primary infection of primary
humanumbilicalvascularendothelialcells(HUVEC),KSHV
activates MEK/ERK, JNK, and p38 MAPK pathways, all of
which activate AP-1, tofacilitate its entry into targetcells and
productive lytic replication at the early acute stage of infec-
tion [169, 170]. Similarly, all three MAPK pathways mediate
both spontaneous and TPA-induced KSHV reactivation in
latent KSHV-infected cells [168, 171, 172]. These pathways
activate and induce the expression of many transcription
factors such as AP-1 and Ets-1. It is interesting that all
three pathways are required for KSHV lytic replication,
suggesting the close interactions of these pathways. Recently,
Pim-1 and Pim-3 kinases are found to mediate KSHV lytic
replication [173]. Of interest, Pim-1 and Pim-3 are induced
in response to physiological and chemical inducers of KSHV
lytic replication. Pim-1 and Pim-3 phosphorylate LANA
on serine residues 205 and 206 and reverse its repressive
eﬀect on the transcription and transactivation function
of RTA. Furthermore, Toll-like receptors (TLRs), which
recognizepathogensandarevitalforthehost innateimmune
responses, also mediate KSHV reactivation [145]. Agonists
of TLR7/8 and vesicular stomatitis virus (VSV) known to
activate these receptors can reactivate KSHV from latency.
These results indicate that secondary infections by other
pathogens such as HIV, other viruses, and bacteria might
trigger KSHV reactivation by activating speciﬁc cellular
pathways.
KSHV itself has evolved multiple mechanisms to manip-
ulate cellular antiapoptotic and survival pathways, each of
which might aﬀect itslife cycle.Asindicated above, pathways
that promote cell growth and survival usually favor KSHV
latency. Suppression of these pathways in latent cells disrupts
latency and reactivates KSHV. For example, the cell survival
pathway NF-κB, which is activated by vFLIP, miR-K1, and8 Advances in Virology
several other viral lytic genes, has inhibitory eﬀect on KSHV
lytic replication [112, 116, 120, 174]. In addition to AP-1,
NF-κB also antagonizes RBP-Jκ to negatively regulate the
expression and transactivation function of RTA [174]. In
KSHV-infected latent cells, inhibition of NF-κBp a t h w a y
disrupts viral latency and activates viral lytic replication
[112]. Nevertheless, as indicated above, the role of NF-κB
pathway in KSHV life cycle is context dependent [115].
It is likely that the balance of AP-1 and NF-κBp a t h w a y s
determines the fate of virus replication status in a given
cell type. If the NF-κB pathway is robust and represses the
AP-1 pathway, KSHV would remain in latency. However,
if AP-1 is strongly activated by other factors and it can
not be repressed by the NF-κB pathway, KSHV would
undergo lytic replication regardless of the status of NF-κB
pathway. This mechanism of regulation might explain the
contradictory role of NF-κB pathway in KSHV life cycle in
diﬀerent cell types. For example, KSHV immediately enters
latency following primary infection in dermal microvascular
endothelial cells (DMVECs) [175, 176]. In contrast, KSHV
undergoes a productive lytic phase, expressing almost all
the lytic genes and producing a high titer of infectious
virions following primary infection of HUVEC [9, 177, 178].
Infection of both HUVEC and DMVEC activates the ERK
pathway; however, infection of HUVEC also activates the
JNK and p38 pathways, while infection of DMVEC robustly
activates the NF-κBp a t h w a y[ 19, 169, 170, 179]. Additional
studies are required to further deﬁne the role of NF-κB
pathwayinKSHVlifecycleindiﬀerentexperimentalsystems.
Consistent with this notion, a recent study showed that
inhibitionoftheprosurvival PI3K-AktpathwayfavorsKSHV
reactivation from latency [180]. Inhibition of the pathway
with Akt inhibitor VIII reactivates KSHV from latency by
increasing RTA expression and activity. Similar to KSHV,
MHV-68 infection induces PI3K-dependent Akt activation,
and lytic replication of MHV-68 is enhanced when PI3K-
Akt pathway is inhibited with both chemical inhibitors and
siRNA knockdown.
3.3. Viral Genome and Genes. Several studies have provided
evidences of epigenetic control of KSHV reactivation. One
study showed that the promoterofRTA isheavily methylated
in latent genome, and TPA treatment not only causes
demethylation ofRTA promoter butalso induces KSHVlytic
replication [181]. In addition, the RTA promoter is highly
responsive to sodium butyrate and trichostatin A (TSA),
inhibitors ofhistone deacetylases [182]. These two inhibitors
target classes I and II histone deacetylases. Recently, we
have shown that inhibition of class III histone deacetylase
SIRT1 also induces RTA expression and activates KSHV lytic
replication [183].
Asstatedabove,mostregions ofthelatentKSHVgenome
contain both activating and repressive histone marks in a
m u t u a l l ye x c l u s i v em a n n e ra sw e l la sP c G ,w h i c hr a p i d l y
change upon reactivation [44, 45]. Inhibition of the expres-
sion of PcG complex protein EZH2 or H3K27me3-speciﬁc
histonedemethylaseswithasmall moleculeinhibitorDZNep
or RNAi knockdown induced KSHV lytic replication [45].
These data indicate that histone modiﬁcations control the
temporal and sequential expression of the lytic gene cascade,
and the PcG proteins play a critical role in controlling KSHV
latency. The regulation of spatial and temporal association of
PcG proteins with the KSHV genome might be crucial for
KSHV life cycle.
Several KSHV genes are essential for lytic replication.
Most of them are expressed early (IE and early genes) during
KSHV lytic replication and thus are essential for the
initiation and completion of the viral lytic cycle. The most
important andbeststudiedIEandearly genesareRTA,MTA,
and K-bZIP.
3.3.1. RTA. Expression of RTA is both necessary and suf-
ﬁcient for KSHV reactivation [184–186]. Genetic deletion
of RTA results in defective reactivation and lytic DNA
replication [187]. RTA autoactivates its own promoter [188]
and transactivates downstream lytic genes including vIL-6
[189, 190], polyadenylated nuclear RNA (Pan) [191], MTA
[192, 193], K-bZIP [192, 193], vIRF1 (ORF-K9) [194],
ORF-K1 [195], small viral capsid protein (ORF65), ORF56,
SOX (ORF37), vOX, and ORF52 [189, 194, 196]. RTA
b i n d st ot h ep r o m o t e r so fi t st a r g e t sb yd i r e c tD N Ab i n d -
ing or protein-protein interactions. Several RTA-activated
promoters contain RRE [197]. Selective ampliﬁcation of
bound sequences in vitro identiﬁed a number of RTA
direct binding targets [198]. Chip-on-Chip genome-wide
screening for RTA direct targets in KSHV-infected BCBL-1
cellsidentiﬁedatotalof19putativeRTAbindingsiteslocated
in the promoters, introns, or exons of KSHV genes. These
targets include ORF8, ORFK4.1, ORFK5, PAN, ORF16,
ORF29, ORF45, RTA, K-bZIP, ORFK10.1, ORF59, ORF-
K12, ORF71/72, vOX/vGPCR (ORF74), ORF-K15, the two
OriLyts, and the miR cluster [199]. Many of these targets
have been experimentally conﬁrmed or identiﬁed in other
screenings [189, 198]. Sequence alignment of all putative
RTA binding sites identiﬁed the consensus binding motif as
TTCCAGGAT(N)(0-16)TTCCTGGGA [199]. Interestingly,
most RTA binding sites identiﬁed in the Chip-on-Chip
screening contain only half or part of this consensus
sequence, suggesting the complexity of RTA transactivation
mechanism. One simple explanation for these variations is
that RTA binds to its targets through interactions with other
viral or cellular regulatory proteins. Indeed, RTA transacti-
vation of ORF-K8 and ORF57 depends on heterogeneous
RREs,and the activation ofORF57promoterrequires an AP-
1b i n d i n gs i t e[ 192]. Similarly, autoactivation of RTA and
RTAtransactivation ofviral lyticpromoterssuchasMTAand
thymidine kinase (TK, ORF21) promoters depend on Sp-1,
octamer-binding protein-1 (Oct-1) and XBP-1 [158, 200–
204]. Several studies have shown that RTA is recruited for
RREs through interaction with RBP-Jκ [205–207]. The RTA-
RBP-Jκ interaction converts the repressor into an activator,
resulting in the activation of viral promoters. Consistent
with these results, RBP-Jκ is usually not detectable in KSHV-
infected latent cells but is signiﬁcantly upregulated during
viral lytic replication, and intracellular-activated Notch1 is
suﬃcienttoreactivate KSHVfromlatency[208].Inaddition,Advances in Virology 9
RTAstimulatesDNAbinding ofRBP-Jκ to activate the Notch
pathway, which allows KSHV to complete the lytic cycle
[209].
RTA transactivation function also dependsonitsinterac-
tions with other proteins. RTA activation of viral promoters
dependson the recruitment of CBP, the SWI/SNFchromatin
remodeling complex, and the TRAP/mediator coactivator
into viral promoters [210]. The Brg1 subunit of SWI/SNF
and the TRAP230 subunit of TRAP/mediator interact
directly with RTA through a short acidic sequence in the car-
boxyl region. Genetic ablation of these interactions abolishes
RTA activation of lytic genes and KSHV lytic replication.
Additionally,RTAinteractswith K-RBP(KSHVRTAbinding
protein), a homologue of the Kruppel-associated box-zinc
ﬁngerproteins(KRAB-ZFPs),foritstransactivation function
[211–213]. The corepressor of K-RBP, Kruppel-associated
box domain-associated protein-1 (KAP-1)/transcriptional
intermediary factor 1beta,acellulartranscriptional repressor
that controls chromosomal remodeling, also participates in
the control of lytic replication [214]. During latency KAP-
1 binds to viral lytic promoters to repress gene expression.
Knockdown of KAP-1 is suﬃcient to induce KSHV reactiva-
tion. Both sumoylation and phosphorylation regulate KAP-1
associationwithheterochromatin.Duringreactivation,RAP-
1 is phosphorylated at Ser 824, resulting in its decreased
sumoylation and binding to the condensechromatin on viral
promoters. Interestingly, RTA induction of viral lytic gene
expression is also negatively correlated with reduced KAP-
1 binding to viral promoters. These evidences point to an
important role of KAP-1 for regulating KSHV latency.
The mechanism of RTA transactivation of K-bZIP is
complex and is involved with an ampliﬁcation process.
K-bZIP physically interacts with and stabilizes the cellu-
lar transcription factor CCAAT/enhancer-binding protein-
alpha (C/EBPα), leading to upregulated expression of
C/EBPα and p21CIP1 proteins followed by G0/G1 cell cycle
arrest [215, 216]. RTA interacts with C/EBPα,a n db o t h
K-bZIP and RTA cooperate with C/EBPα to activate the
K-bZIP promoter through binding to a proximal C/EBPα
binding site that also serves as an RRE [215]. C/EBPα also
activates the promoters of RTA, PAN, and MTA through
direct binding of the C/EBPα and RTA complex [216, 217].
Therefore, besides direct DNAbinding, RTA cooperates with
diﬀerentcellulartranscriptional factorstoupregulatevarious
downstream viral genes.
Interestingly, RTA exhibits a ubiquitin E3 ligase activ-
ity and targets multiple cellular and viral proteins for
proteasome-mediated degradation [218]. One of the RTA
degradation targets is IRF-7, a key mediator of type I IFN
induction [219]. Since IFN signaling plays an important role
in suppressing viral lytic replication, this ﬁnding suggests
that RTA might overcome the host innate immune defenses
during KSHV reactivation. Another cellular protein targeted
by RTA is Hey1, which interacts with repressor mSin3A.
Hey1 degradation disrupts the interaction between Hey1
and mSin3A. Hey1 suppresses RTA expression by direct
binding to the RTA promoter [220]. By targeting Hey1 for
degradation, RTA upregulates its own expression. Together,
these results suggest that RTA regulates viral lytic replication
by promoting protein degradation of several cellular repres-
sors.
Finally, RTA might contribute to KSHV lytic DNA repli-
cation [221]. The left OriLyt (OriLyt-L) lies between ORF-
K4.2 and -K5 and is composed of a region encoding various
transcription factor binding sites, an A+T-rich region, and a
G+C repeat. The right OriLyt (OriLyt-R) is mapped between
ORF69 and vFLIP and is an inverted duplication of OriLyt-
L. Interestingly, each OriLyt contains an RRE [222]. It was
shownthatbindingofRTAtothisRREisessentialforOriLyt-
dependent DNA replication [167, 222, 223]. The presence
of this cis-element and a downstream TATA box suggests
that this region serves as an RTA-dependent promoter, and
a transcription event may be necessary for OriLyt-dependent
DNA replication.
3.3.2. MTA. MTA is required for KSHV lytic replication.
Genetic knockout of MTA abolishes KSHV productive lytic
replication [224, 225]. MTA protein possesses domains with
putative transcriptional and posttranscriptional functions
[226]. MTA itself does not enhance the expression of RTA
or other lytic genes alone. Rather, it binds to proteins
with transcriptional regulatory functions. Forexample,MTA
synergizes with RTA to regulate expression of viral genes
in a promoter- and cell line-speciﬁc manner [226, 227].
MTA and RTA directly interact with each other, and both
proteins are found in RTA promoter during lytic replication.
A DNA element conserved in multiple KSHV promoters
is necessary but not suﬃcient for this synergy. A putative
A/T hook domain within MTA mediates DNA binding and
transcriptional initiation [226]. When RTA transactivation
function is eliminated, MTA no longer aﬀects the expression
of viral genes suggesting that their synergistic eﬀect depends
on RTA’s transactivation function. Thus, MTA facilitates
the cascade of viral gene expression during lytic replication
through physical interaction with RTA.
MTA enhances the accumulation of speciﬁc viral and
cellularmRNAs[228].Thiseﬀectismoreeﬃcientforintron-
less RNAs and is independent of transcriptional regulation
[229, 230]. MTA shuttles between nuclei and cytoplasm, and
promotesnuclearexportofnonsplicedRNAs[229,231,232].
Besides, MTA stabilizes RNAs and stimulates translation of
mRNAs that contain internal ribosome entry sites [233].
3.3.3. K-bZIP. K-bZIP physically interacts with RTA. This
interaction involves K-bZIP’s basic domain (aa122-189)
and a speciﬁc RTA region (aa499-550) [234]. In contrast
to MTA, K-bZIP represses RTA transactivation of MTA
promoter in a dose-dependent manner [212, 213]. K-bZIP
also represses the RTA autoactivation [234]. A K-bZIP
mutant lacking the RTA interaction domain fails to repress
RTA-mediatedtransactivation,suggestingtherequirementof
this interaction for K-bZIP’s repression eﬀect. Interestingly,
such repression is not seen for the PAN promoter. Thus,
K-bZIP repression of RTA-mediated transactivation is likely
promoter dependent.
K-bZIP is sumoylated at the lysine 158 residue and
is associated with Ubc9 both in a cell-free system and in10 Advances in Virology
BCBL-1 cells [235]. K-bZIP sumoylation is required for
transcription repression. Acting as a SUMO adaptor, K-
bZIP recruits Ubc9 to speciﬁc viral promoters to exert
its transcriptional repression activity [235]. Together, these
resultssuggestthatK-bZIPisinvolvedinafeedbackcircuitto
turn oﬀ its own expression and possibly other RTA-activated
lyticgenes.Nevertheless,agenome-wideanalysisofK-bZIP’s
transcriptional eﬀect on 83 putative KSHV gene promoters
showed that34viral promoters were activated byRTA and 21
promoters by K-bZIP alone [236]. However, when RTA and
K-bZIP were combined, 3 RTA-responsive promoters were
repressed by K-bZIP. Therefore, K-bZIP might also transac-
tivate some viral lytic genes during KSHV reactivation.
K-bZIP interacts with some other proteins such as a
serine/threonine protein kinase (vPK) encoded by ORF36 to
exert its regulatory eﬀect [237]. During reactivation, vPK,
K-bZIP, and a polymerase processivity factor are colocalized
with the viral DNA replication/transcription compartments,
and both K-bZIP and vPK are recruited to K-bZIP target
promoters and OriLyt. vPK strongly phosphorylates K-bZIP
at threonine 111 [238], resulting in a resistance of K-bZIP to
sumoylation and a reduction of its transcription repression
activity [238]. Thus, K-bZIP and vPK cooperate to modulate
viral transcription and replication [237].
The fact that K-bZIP binds to OriLyts suggests a role
f o rK - b Z I Pi nl y t i cD N Ar e p l i c a t i o n[ 167]. LANA also
binds to OriLyts and represses origin-dependent lytic DNA
replication. However, this LANA repression eﬀect can be
overcome by K-bZIP [239]. Since LANA interacts with
OriLyts in the absence of K-bZIP, its suppression of lytic
DNA replication is likely mediated by direct DNA binding.
In contrast, interaction of K-bZIP with OriLyts depends on
LANA expression [239]. Therefore, origin-dependent DNA
replicationrequiresnotonlythecorereplicationproteinsbut
also both RTA and K-bZIP.
Collectively, these studies have shown that K-bZIP has
dual functions in modulating KSHV life cycle: on one
hand, it facilitates lytic DNA replication, on the other hand,
it serves as a feedback modulator to repress lytic gene
expression. These two functions might be independent of
each other [240]. Consistent with these results, knock-down
of K-bZIP in KSHV-infected cells BCBL-1 and BC-3 led
to dramatic decreases in the expression of RTA, MTA and
ORF26 transcripts, reduced RTA and ORF-K8.1 protein
levels, and severely impaired viral DNA replication and
virion production [241]. Thus, K-bZIP is essential for lytic
gene expression, DNA replication, and virus production in
PEL cells.
4.Conclusions
Remarkable advancements have been made in our under-
standing of the mechanisms of KSHV latency and lytic
replication in the last several years (Figure 1). Given the
critical roles of both replication modes in viral life cycle and
pathogenesis, these progresses have signiﬁcantly advanced
the biology of KSHV and should provide the scientiﬁc
basis for developingnovel intervention approaches to inhibit
KSHV infection and KSHV-induced malignancies. With the
rapid advancement of novel technologies such as high-
throughput sequencing and real-time high-resolution imag-
ing, it is expected that more comprehensive understanding
of the molecular basis of KSHV life cycle will be made in the
next few years.
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